CDSCO approves antibody cocktail drug for restricted emergency use to treat mild Covid-19 cases
CDSCO approves use of antibodies cocktail drug (Casirivimab and Imdevimab) for restricted emergency use to treat mild to moderate Covid-19 in adults and paediatric patients.
advertisement
Health workers inspect Covid-19 patients at a hospital in New Delhi. (Photo credit: PTI).
The Indian regulatory body, Central Drugs Standards Control Organisation (CDSCO), has approved the use of antibodies cocktail drug (Casirivimab and Imdevimab), for restricted emergency used to treat mild to moderate Covid-19 in adults and paediatric patients (12 years or weighing more than at least 40 kg).
Antibodies Cocktail Drug can be a game-changer in Covid-19 treatment, especially when these are recommended to be given at the early stages of laboratory-confirmed SARS-CoV-2 infection positive result. Theis is preferebly administered within 10 days of symptoms onset.
This emergency use authorisation (EUA) will now enable Roche to import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla Limited.
Millions Of Vials Of Remdesivir Exported, Now Indians Suffering Due To Shortage: Delhi HC Raps Centre
Remdesivir, an antiviral drug which was originally developed to treat Hepatitis C, is being used in many parts of India to treat Covid-19 patients. File Photo Outlook Web Bureau 2021-04-27T20:17:05+05:30 Millions Of Vials Of Remdesivir Exported, Now Indians Suffering Due To Shortage: Delhi HC Raps Centre outlookindia.com 2021-04-27T20:21:11+05:30
Also read
Taking cognizance of the shortage of Remdesivir, an antiviral drug used in the treatment of Covid-19, the Delhi High Court on Tuesday said that the export of millions of vials of the drug has caused a scarcity of the same in the country.
The announcement comes days after the Centre held a meeting with all-existing manufacturers of the drug and other stakeholders in order to discuss steps taken to increase production and supply and reduce prices of Remdesivir
URL copied
Major manufacturers of Remdisivir have reduced the price considerably. (Photo for representation only)
The demand for Remdesivir, an injectable medicine, has soared manifold amid skyrocketing coronavirus cases in the country. Amid reports of several states pressing the alarm button over the acute shortage of the key antiviral drug, manufacturers have now decided to reduce the price.Â
Union Minister for Chemicals and Fertilizers DV Sadananda Gowda on Friday said that major manufacturers of Remdisivir have reduced the price considerably. On Govtâs intervention, major manufacturers of Remdesivir have voluntarily reduced its MRP ranging from Rs 5400 to less than Rs 3500 by 15.04.2021. This will support PM @narendramodi s efforts to fight #COVID19, Gowda said in his tweet.